In the ZETA-1 Phase 2 trial, APX3330 did not meet the primary endpoint (% of patients with a >= 2-step improvement in DRSS at week 24 in the study eye).
A “key” secondary endpoint relating to each patient’s non-study eye was met.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”